Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy in Recurrent Pediatric Brain Tumors
2010-023691-33Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Apr 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide and 2 more in medulloblastoma, ependymoma and Atypical teratoid rhabdoid tumor (ATRT), sponsored by Medical University of Vienna. Primary endpoint: Clinical objective treatment response at 6 months. Started Apr 2011; status: active.
02
Drugs
bevacizumabthalidomidecelecoxibfenofibrateetoposide
03
Conditions
medulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on 2010-023691-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023691-33.